Last reviewed · How we verify
V158866
At a glance
| Generic name | V158866 |
|---|---|
| Sponsor | Vernalis (R&D) Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury (PHASE2)
- Single and Multiple Ascending Dose Study of V158866 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V158866 CI brief — competitive landscape report
- V158866 updates RSS · CI watch RSS
- Vernalis (R&D) Ltd portfolio CI